IRIS
MARCHICA, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.194
NA - Nord America 1.034
AS - Asia 313
Continente sconosciuto - Info sul continente non disponibili 6
AF - Africa 5
OC - Oceania 1
Totale 2.553
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.020
IE - Irlanda 326
SE - Svezia 288
CN - Cina 228
IT - Italia 213
AT - Austria 130
DE - Germania 81
TR - Turchia 68
FI - Finlandia 56
BE - Belgio 25
RO - Romania 20
CA - Canada 13
FR - Francia 12
GB - Regno Unito 11
IN - India 9
NL - Olanda 8
EU - Europa 6
ES - Italia 5
UA - Ucraina 4
BG - Bulgaria 3
CZ - Repubblica Ceca 3
IR - Iran 3
LU - Lussemburgo 3
SC - Seychelles 3
KH - Cambogia 2
NG - Nigeria 2
SM - San Marino 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
BN - Brunei Darussalam 1
BZ - Belize 1
CH - Svizzera 1
DK - Danimarca 1
HK - Hong Kong 1
MD - Moldavia 1
RS - Serbia 1
Totale 2.553
Salva come PNG Salva come JPEG
Città #
Chandler 329
Dublin 326
Vienna 112
Parma 102
Ann Arbor 93
Dearborn 67
Izmir 54
Nanjing 51
Princeton 44
Beijing 41
Wilmington 27
Brussels 25
Bremen 23
Shenyang 23
Helsinki 21
San Mateo 15
Hebei 14
Jinan 13
Kunming 13
Nanchang 13
Kocaeli 12
Modena 11
Focsani 10
Redmond 10
Ashburn 9
Milan 9
Fairfield 8
Jiaxing 8
Toronto 8
Woodbridge 8
Changsha 7
Hefei 7
Norwalk 7
Guangzhou 6
Savignano sul Rubicone 6
Tianjin 6
Zhengzhou 6
Boardman 5
Des Moines 5
Düsseldorf 5
Houston 5
Jacksonville 5
Madrid 5
Washington 5
Palermo 4
Rio Saliceto 4
Romainville 4
Torino 4
Ahmedabad 3
Bologna 3
Cesena 3
Fremont 3
Gorgonzola 3
Hangzhou 3
London 3
Nürnberg 3
Ottawa 3
Redwood City 3
Reggio Emilia 3
Rho 3
Sofia 3
St Louis 3
Amsterdam 2
Arcevia 2
Borås 2
Chengdu 2
Cornaredo 2
Edinburgh 2
Grafing 2
Lagos 2
Luxembourg 2
Manchester 2
Phnom Penh 2
Sabz 2
Seattle 2
Taiyuan 2
Taizhou 2
Tampa 2
Turku 2
Vignola 2
Xian 2
Ankara 1
Atlanta 1
Augusta 1
Bandar Seri Begawan 1
Belgrade 1
Belize City 1
Bradford 1
Castel San Giovanni 1
Castelfranci 1
Castelfranco Emilia 1
Catania 1
Central 1
Charlotte 1
Chicago 1
Chisinau 1
Dallas 1
Denver 1
Dubai 1
Frankfurt am Main 1
Totale 1.694
Salva come PNG Salva come JPEG
Nome #
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 86
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 85
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 83
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 82
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 81
Possible targets to treat myeloma-related osteoclastogenesis 80
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 79
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 78
Novel targets for the treatment of relapsing multiple myeloma 76
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 76
Oncolytic virotherapy and microenvironment in multiple myeloma 74
A simplified sars-cov-2 pseudovirus neutralization assay 70
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 69
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 66
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 65
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 64
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 61
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 61
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 60
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 59
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 56
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 56
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 55
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 54
Amlexanox inhibition of TBK1/IKK epsilon Signaling Is a Novel Therapeutic Approach for Multiple Myeloma-Induced Bone Disease. 53
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 52
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 51
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 51
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 50
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 49
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression 49
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma 47
Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively 47
Role of Galectins in Multiple Myeloma. 46
Concomitant primary hyperparathyroidism in patients with multiple myeloma: A possible link? 45
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 45
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 44
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 43
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 43
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 43
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 40
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 40
MYELOMA CELLS FROM THE BONE MARROW TO THE SKIN: HOW? 37
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 35
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 22
The impact of CD56 expression in smoldering myeloma patients on early progression 17
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 12
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4) 11
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 10
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 4
Totale 2.662
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.228
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.228
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019112 0 0 0 7 10 1 1 1 7 10 71 4
2019/2020350 77 56 8 8 13 58 46 8 24 36 10 6
2020/2021250 30 4 7 7 40 8 15 22 44 28 16 29
2021/2022278 6 10 10 23 6 7 43 35 15 13 19 91
2022/20231.346 125 137 91 98 104 134 74 88 387 21 59 28
2023/202499 31 48 20 0 0 0 0 0 0 0 0 0
Totale 2.662